WallStSmart

Sanofi ADR (SNY)vsThe TJX Companies Inc (TJX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

The TJX Companies Inc generates 27% more annual revenue ($60.37B vs $47.35B). SNY leads profitability with a 16.0% profit margin vs 9.1%. TJX appears more attractively valued with a PEG of 3.42. TJX earns a higher WallStSmart Score of 56/100 (C).

SNY

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 6.5Value: 5.3Quality: 5.0

TJX

Buy

56

out of 100

Grade: C

Growth: 6.7Profit: 7.5Value: 3.3Quality: 6.3
Piotroski: 5/9Altman Z: 3.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

SNYUndervalued (+25.0%)

Margin of Safety

+25.0%

Fair Value

$62.70

Current Price

$43.31

$19.39 discount

UndervaluedFair: $62.70Overvalued
TJXOvervalued (-6.9%)

Margin of Safety

-6.9%

Fair Value

$147.47

Current Price

$153.36

$5.89 premium

UndervaluedFair: $147.47Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SNY4 strengths · Avg: 8.8/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Market CapQuality
$103.45B9/10

Large-cap with strong market position

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$1.68B8/10

Generating 1.7B in free cash flow

TJX5 strengths · Avg: 9.0/10
Return on EquityProfitability
59.1%10/10

Every $100 of equity generates 59 in profit

Altman Z-ScoreHealth
3.3010/10

Safe zone — low bankruptcy risk

Market CapQuality
$169.59B9/10

Large-cap with strong market position

EPS GrowthGrowth
27.9%8/10

Earnings expanding 27.9% YoY

Free Cash FlowQuality
$2.63B8/10

Generating 2.6B in free cash flow

Areas to Watch

SNY3 concerns · Avg: 2.3/10
Return on EquityProfitability
6.6%3/10

ROE of 6.6% — below average capital efficiency

PEG RatioValuation
3.762/10

Expensive relative to growth rate

EPS GrowthGrowth
-11.7%2/10

Earnings declined 11.7%

TJX3 concerns · Avg: 3.3/10
P/E RatioValuation
31.5x4/10

Premium valuation, high expectations priced in

Price/BookValuation
16.7x4/10

Trading at 16.7x book value

PEG RatioValuation
3.422/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : SNY

The strongest argument for SNY centers on Price/Book, Market Cap, Operating Margin. Profitability is solid with margins at 16.0% and operating margin at 20.0%.

Bull Case : TJX

The strongest argument for TJX centers on Return on Equity, Altman Z-Score, Market Cap.

Bear Case : SNY

The primary concerns for SNY are Return on Equity, PEG Ratio, EPS Growth.

Bear Case : TJX

The primary concerns for TJX are P/E Ratio, Price/Book, PEG Ratio.

Key Dynamics to Monitor

SNY profiles as a mature stock while TJX is a value play — different risk/reward profiles.

TJX carries more volatility with a beta of 0.64 — expect wider price swings.

TJX is growing revenue faster at 8.5% — sustainability is the question.

TJX generates stronger free cash flow (2.6B), providing more financial flexibility.

Bottom Line

TJX scores higher overall (56/100 vs 51/100). SNY offers better value entry with a 25.0% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Sanofi ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.

The TJX Companies Inc

CONSUMER CYCLICAL · APPAREL RETAIL · USA

The TJX Companies, Inc. (abbreviated TJX) is an American multinational off-price department store corporation, headquartered in Framingham, Massachusetts.

Want to dig deeper into these stocks?